BioSpace News Archive

Electrosurgery is a minimally invasive surgical procedure in which radiofrequency alternating current is used to increase intracellular temperature.

Dr. Jorge Gallardo Ballart has announced in the Board of Directors’ session on Friday 18th February, his intention to retire from his positions of Chairman of the Board of Directors and Board member with effect as of the end of the General Shareholders Meeting of Almirall, S.A. that will take place next 6 May 2022.

Positive topline results from the pivotal DESTINY-Breast04 phase 3 trial showed ENHERTU® demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival in patients with HER2 low unresectable and/or metastatic breast cancer regardless of hormone receptor status versus physician’s choice of chemotherapy, which is the current standard of care.

OMass Therapeutics is pleased to confirm that it will be presenting at a number of upcoming banking, business and scientific conferences, as detailed below.

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2021 financial results before the market opens on Thursday, February 24, 2022.

The recent developments in medical sector such as invisible devices, and minimally invasive surgeries are the key factors promoting the growth of the global bone conduction hearing devices market.

Arterial thrombosis is the formation of blood clots inside the artery. The formed clot usually does not show any kind of symptoms until it restricts the blood flow through the circulatory system.

Amylin analogs are used to treat diabetes. Physiological amylin and amylin analogs have similar properties.

Nicox SA, an international ophthalmology company, announced that the Chinese National Intellectual Property Administration has granted the company a formulation patent for NCX 470, its lead product candidate in development for patients with open-angle glaucoma or ocular hypertension, extending coverage in China to 2039.

Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of Personal Genome Diagnostics Inc.